Amlexanox

Amlexanox

SCHEMBL16216162

[2H]CC([2H])(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Amlexanox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDE4D known ✓ Q08499 1/20 0.82
▸ TBK1 Q9UHD2 20/20 0.82
▸ IKBKE Q14164 12/20 0.82
▸ KDM4E B2RXH2 1/20 0.82
▸ NPC1 O15118 1/20 0.82
▸ ABCC4 O15439 1/20 0.82
▸ TTR P02766 1/20 0.82
▸ GAA P10253 1/20 0.82
▸ PKM P14618 1/20 0.82
▸ ADRA1A P35348 1/20 0.82
▸ OPRD1 P41143 1/20 0.82
▸ RAB9A P51151 1/20 0.82
▸ PDE3A Q14432 1/20 0.82
▸ GPR35 Q9HC97 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amlexanox SCHEMBL16216144 0.95 TBK1 (0.87) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL5058549 0.90 TBK1 (1.00) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL29642 0.90 TBK1 (1.00) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL29381739 0.90 TBK1 (1.00) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL29441547 0.90 TBK1 (1.00) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL2907023 0.89 TBK1 (0.98) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL2908304 0.89 TBK1 (0.98) TBK1IKBKEKDM4ENPC1ABCC4
Amlexanox SCHEMBL2902814 0.89 TBK1 (0.98) TBK1IKBKEKDM4ENPC1ABCC4
SCHEMBL19180576 0.86 TBK1 (0.62) TBK1IKBKEKDM4ENPC1ABCC4
SCHEMBL10512977 0.84 TBK1 (0.80) TBK1IKBKEKDM4ENPC1ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 — — US disclosed
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 — — US disclosed
US-20160251366-A1 DEUTERATED AMLEXANOX THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2016-09-01 — — US disclosed
US-9365581-B2 Deuterated amlexanox THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-06-14 — — US disclosed
US-20160060271-A1 DEUTERATED AMLEXANOX THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-03-03 — — US disclosed
US-8946424-B2 Deuterated amlexanox THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-02-03 — — US disclosed
US-20140329848-A1 DEUTERATED AMLEXANOX THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329848-A1 DEUTERATED AMLEXANOX DDX3X, DHX30, HAX1 PDE4D 533/4885TBK1 3563/4885IKBKE 3768/4885
US-20160060271-A1 DEUTERATED AMLEXANOX AADAC, GPR119, IAPP PDE4D 1799/4885TBK1 1397/4885IKBKE 1010/4885
US-20160251366-A1 DEUTERATED AMLEXANOX DDX3X, DHX30, HAX1 PDE4D 533/4885TBK1 3563/4885IKBKE 3768/4885
US-20170217980-A1 AMLEXANOX ANALOGS GPR119, GLP1R, IRS1 PDE4D 827/4885TBK1 494/4885IKBKE 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback